Early last year, the GenEthics Consortium (GEC)
of the Washington Metropolitan Area convened at George
Washington University to consider a complex case about
genetic testing for Alzheimer disease (AD). The GEC consists
of scientists, bioethicists, lawyers, genetic counselors,
and consumers from a variety of institutions and affiliations.
Four of the 8 co-authors of this paper delivered presentations
on the case. Supplemented by additional ethical and legal
observations, these presentations form the basis for the
following discussion.